MedTrace Logo

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03127956 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 748

Last updated 2021-07-20

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris

Conditions

  • Acne Vulgaris

Interventions

DRUG

Olumacostat Glasaretil Gel, 5.0%

Gel containing Olumacostat Glasaretil

Sponsors & Collaborators

  • Dermira, Inc.

    lead INDUSTRY

Principal Investigators

  • Beth Zib · Dermira, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-21
Primary Completion
2018-04-27
Completion
2018-04-27
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03127956 on ClinicalTrials.gov